English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
Help us to find a cure for CML
Your contribution supports research in CML and helps to make cure a reality for patients with CML one day.
Please donate now to drive research in CML.
Over the past decades, significant advances have been made in the treatment and monitoring of CML. But a cure for CML is still an unmet need.
“A concerted global effort working towards a cure is imperative. The iCMLf is uniquely positioned to drive this effort.”
– Tim Hughes, iCMLf Chairman
The iCMLf has launched global research collaborations to accelerate the development of more effective and safer treatment strategies with the view that ultimately these will lead to a cure for CML.
Learn more about the iCMLf CURE Consortium >>
Our mission is to improve the outcomes for patients with CML globally.
Let's work together on this to drive research on a cure for CML.
Every contribution counts
Please note: fields marked with a star (*) are required.
Donate by Credit Card
CML Publications 2020
CML Publications 2020
| Clinical Publications | Scientific Publications |
| December 2020 | |
| TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukemia Claudiani S et al. Br J Haematol, December 2020 (epub ahead of print) |
Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission Vigón L et al. J Clin Med, December 2020 – open access publication |
| Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom? Atallah E and Schiffer CA. Haematologica, December 2020 – open access publication |
Targeting of the Alox12-12-HETE in blast crisis chronic myeloid leukemia inhibits leukemia stem/progenitor cell function (Gao S et al. Cancer Manag Res, December 2020) – open access publication |
|
Why is it critical to achieve a deep molecular remission in chronic myeloid leukemia? |
Inhibitors targeting STAT5 signaling in myeloid leukemias: New Tetrahydroquinoline derivates with improved antileukemic potential (Prié G et al. ChemMedChem, December 2020) |
| BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analysed by NGS (Soverini S et al. Leukemia, December 2020) (epub ahead of print) |
Let-7b regulates the Adriamycin resistance of chronic myelogenous leukemia by targeting AURKB in K562/ADM cells (Zhou X etc. Leuk Lymphoma, December 2020) |
| First-generation vs second-generation tyrosine kinase inhibitors: which is best at diagnosis of chronic-phase chronic myeloid leukemia (Oehler VG. Hematology Am Soc Hematol Educ Program, December 2020) – open access publication |
Evidence that knock down of GSK-3beta in chronic myelogenous leukemia cells augments IFN-gamma-induced apoptosis (Kauffmann MR et al. Leuk Res, December 2020) |
| Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice (Breccia M et al. Expert Rev Hematol, December 2020) |
Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis (Tanabe Y et al. Blood Adv, December 2020) – open access publication |
| Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response (Pagnano KBB et al. Am J Hematol, December 2020) – open access publication |
Novel strategies to eradicate resistant cells in chronic myeloid leukemia |
|
Management of chronic myeloid leukemia during pregnancy among patients with tyrosine kinase inhibitor: |
Widespread aberrant alternative splicing despite molecular remission in chronic myeloid leukaemia patients (Schmitz U et al. Cancers (Basel), December 2020) – open access publication |
|
Quality of life and symptom burden with first- and second generation tyrosine kinase inhibitors in patients with chronic-phase chronic myeloid leukemia |
Circadian clock gene Period2 suppresses human chronic myeloid leukemia cell proliferation (Wang N et al. Exp Ther Med, December 2020) – open access publication |
|
Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients |
|
|
Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for CML: |
|
|
Impact of anemia on the outcomes of chronic phase chronic myeloid leukemia in TKI era |
|
| November 2020 | |
| How to manage CML patients with comorbidities (Cortes J. Blood, November 2020) – open access publication |
Characterization of p190 BCR-ABL chronic myeloid leukemia reveals specific signalling pathways and therapeutic targets (Adnan-Awad S et al. Leukemia, November 2020) (epub ahead of print) |
| Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia (Abaza Y et al. Am J Hematol, November 2020) |
P19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signalling pathway in CML (Kuang Y et al. Blood Cells Mol Dis, November 2020) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: Updates from the LAST study on patient-reported outcomes and biomarkers for relapse (Braun TP and Druker BJ. JAMA Oncol, November 2020) |
AMD1 is required for the maintenance of leukemia stem cells and promotes chronic myeloid leukemic growth (Sari IN et al. Oncogene, November 2020) (epub ahead of print) |
| The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes (Sasaki K et al. Am J Hematol, November 2020) (epub ahead of print) |
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase (Manley PW et al. Leuk Res, November 2020) |
| Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: A nonrandomized clinical trial (Atallah E et al. JAMA Oncol, November 2020) (epub ahead of print) |
|
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: update form the LAST study on patient-reported outcomes and biomarkers for relapse (Braun TP and Druker BJ. JAMA Oncol, November 2020) (epub ahead of print) |
|
| Handling challenging questions in the management of chronic myeloid leukemia: When is it safe to stop tyrosine kinase inhibitors? (Rea D. Blood Adv, November 2020) – open access publication |
|
| Increased tumor burden in patients with CML after 36 months of imatinib discontinuation (Diral E et al. Blood, November 2020) |
|
| There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge (Ross DM and Hughes TP. Br J Haematol, November 2020) (epub ahead of print) |
|
| Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia (Efficace F et al. Leuk Lymphoma, November 2020) (epub ahead of print) |
|
| Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia (Clark SE et al. J Oncol Pharm Pract, November 2020) (epub ahead of print) |
|
|
Standardization of BCR-ABL1 p210 monitoring: From nested to digital PCR |
|
| Point: Is there a best duration of deep molecular response to achieve therapy-free remission in chronic myeloid leukemia? (Gale RP and Saglio G. Br J Haematol, November 2020) (epub ahead of print) |
|
| A retrospective analysis about frequency of monitoring in Italian chronic myeloid leukemia patients after discontinuation (Dragani M et al. J Clin Med, November 2020) – open access publication |
|
| Tyrosine kinase inhibitor treatment discontinuation in CML: patient views (Tromp VNMF et al. Leuk Lymphoma, November 2020) (epub ahead of print) – open access publication |
|
| October 2020 | |
| Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence and recommendations (Abruzzese E et al. Ther Adv Hematol, October 2020) - open access publication |
Recent advances in BCR-ABL tyrosine kinase inhibitors for overriding T315I mutation (Liu J et al. Chem Biol Drug Des, October 2020) (epub ahead of print) |
| Comparison of droplet digital PCR versus qPCR measurements on the International Scale for the molecular monitoring of chronic myeloid leukemia patients (Cortés AA et al. Mol Diagn Thera, October 2020) |
Delineation of target expression profiles in CD34+/CD38- and CD34+/CD38+ stem cell and progenitor cells in AML and CML (Herrmann H et al. Blood Adv October 2020) – open access publication |
| The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with CML in a practice-based cohort (Sato E et al. Cancer Med, October 2020) (epub ahead of print) - open access publication |
Increased expression of TIGIT/CD57 in peripheral blood/bone marrow NK cells in patients with chronic myeloid leukemia (Yao D et al. Biomed Res Int, October 2020) – open access publication |
| Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom? (Atallah E and Schiffer CA. Haematologica, October 2020) – open access publication |
AMP-activated protein kinase activation primes cytoplasmic translocation and authophagic degradation of the BCR-ABL protein in CML cells (Koyama D et al. Cancer Sci, October 2020) (epub ahead of print) – open access publication |
| Chronic myeloid leukemia, Version 2.2021, NCCN Clinical Practice Guidelines (Deininger MW et al. J Natl. Compr Canc Netw, October 2020) – open access publication |
In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features (Tusa I et al. Target Oncol, October 2020) – open access publication |
| Chronic myeloid leukemia in solid organ transplant patients: a case series (Amitai I et al. Int J Hematol, October 2020) (epub ahead of print) |
PD-1 expressing CD56-negative NK cell expansion is a hallmark of chronic NK cell activation during dasatinib treatment (Ishiyama KI et al. Cancer Sci, October 2020) (epub ahead of print) – open access publication |
| Treatment outcomes in chronic myeloid leukemia: Does one size fit all? (Garcia-Horton A and Lipton JH. J Natl Compr Canc Netw, October 2020) – open access publication |
CytoGPS: A large-scale karyotype analysis of CML data (Abrams ZB et al. Cancer Genet, October 2020) (epub ahead of print) |
| Favourable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib (Mulas O et al. Hematol Oncol, October 2020) |
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signalling complex (Gregor T et al. Cell Mol Sci, October 2020) |
| On the road to treatment-free remission in chronic myeloid leukemia: What about ‘the others’? (Stagno F et al. Expert Rev Anticancer Ther, October 2020) (epub ahead of print) |
DYRK2 controls a key regulatory network in chronic myeloid leukemia (Park CS and Lacorazza HD. Exp Mol Med, October 2020) (epub ahead of print) - open access publication |
| Case series of chronic myeloid leukemia patients who maintained deep molecular response (DMR) with very low-dose ponatinib: experience in discontinuing low-dose ponatinib and treatment-free remission (TFR) outcomes (Cohen J et al. Leuk Lymphoma, October 2020) |
Detection of residual disease in CML utilizing genome next generation sequencing reveals persistence of differentiated Ph(+) B cells but not bone marrow/stem progenitors (Karigane D et al. Leuk Lymphoma, October 2020) (epub head of print) |
| Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favourable in daily clinical practice (Zackova D et al. Leuk Lymphoma, October 2020) (epub ahead of print) |
Examination of clinically-derived p210 BCR/ABL1 RhoGEF mutations in a murine model marrow transplantation of CML (Ciccarelli BT et al. Leuk Res, October 2020) |
| September 2020 | |
| Why is it critical to achieve a deep molecular response in chronic myeloid leukemia? (Branford S. Haematologica, September 2020) – open access publication |
CML – Not only BCR-ABL1 matters (Rinke J et al. Best Pract Res Clin Haematol, September 2020) |
| Breakpoints mapping of a t(9;22;12) chronic myeloid leukemia patient with e14a3 BCR-ABL1 transcript using nanopore sequencing (Zhao H et al. J Gene Med, September 2020) (epub ahead of print) |
Declaration of BCR-ABL1 independence (Zhao H and Deininger MW. Leukemia, September 2020) |
| Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia (Shanmunagathan N et al. Blood, September 2020) (epub ahead of print) |
Efficacy of tyrosine kinase inhibitors on a mouse chronic myeloid leukemia model and chronic myeloid leukemia stem cells (Tanaka Y et al. Exp Hematol, September 2020) |
| Incidence of deep molecular responses and treatment-free remission in de novo CP-CMO patients (Etienne G et al. Cancers(Basel), September 2020) – open access publication |
Checkpoint kinase-1 inhibitors and etoposide exhibit a strong synergistic anticancer effect on chronic myeloid leukemia cell line K562 by impairing homologenous recombination DNA damage repair (Fan Z et al. Oncol Rep, September 2020) (epub ahead of print) - open access publication |
| Erythropoietin treatment in chronic myeloid leukemia patients treated with frontline imatinib who developed anaemia (Cesini L et al. Eur J Hematol, September 2020) |
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor chronic myeloid leukemia cells (He B et al. Biomed Pharmacother, September 2020) – open access publication |
| Treatment-free remission in chronic myeloid leukemia harbouring atypical BCR-ABL1 transcripts (Dragani M et al. Mediterr J Hematol Infect Dis, September 2020) – open access publication |
BCR-ABL allosteric inhibitors: Where we are and where we are going to (Carofiglio F et al. Molecules, September 2020) – open access publication |
| Unravelling surviving expression in chronic myeloid leukemia: Molecular interactions and clinical implications (Bernardo PS et al. Blood Rev, September 2020) |
|
| Second-line dasatinib therapy improved compliance and deep molecular responses in imatinib-intolerant chronic myeloid leukemia patients (Markovic U et al. Anticancer Res, September 2020) |
|
| Impact of the BCR-ABL1 transcript type on clinical and biological parameters and molecular response in patients with chronic myeloid leukemia (Nachi M et al. Hematol Oncol Stem Cell Ther, September 2020) – open access publication |
|
| Response and adherence to nilotinib in daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotonib (Boons CCLM et al. Eur J Pharmacol, September 2020) – open access publication |
|
| August 2020 | |
| Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years? (Yilmaz U & Eskazan AE. Expert Rev Hematol, August 2020) (epub ahead of print) - open access publication |
SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem cell disorders (Kaiser A et al. Leukemia, August 2020 |
| A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5) – AGMT-CML1 (Heibl S et al. Hematol Oncol, August 2020) (epub ahead of print) |
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses (Adnan Awad S et al. Leukemia, August 2020) (epub ahead of print) – open access publication |
| Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs (Sharf G et al. Leukemia, August 2020) – open access publication |
Signal-transducing adapter protein-1 is required for maintenance of leukemic stem cells in CML (Toda J et al. Oncogene, August 2020) – open access publication |
| Low-dose tyrosine kinase inhibitors before treatment discontinuation do not repair treatment-free remission in chronic myeloid leukemia patients: Results of a retrospective study (Cayassials E et al. Cancer, August 2020) – open access publication |
A high-content cytokine screen identifies myostatin propeptides as a positive regulator of primitive chronic myeloid leukemia cells (von Palffy S et al. Haematologica, August 2020) – open access publication |
| Epidural myeloid sarcoma a the presenting symptom of chronic myeloid leukemia blast crisis (Slouma M et al. Clin Rheumatol, August 2020) – open access publication |
Nuclear receptors as potential therapeutic targets for myeloid leukemia (Pan P & Chen X. Cells, August 2020) |
| Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT (He JB et l. Int J Cancer, August 2020) – open access publication |
In vitro comparison of the effects of imatinib and ponatinib on chronic myeloid leukemia progenitor/stem cell features (Tusa I et al. Target Oncol, August 2020) (epub ahead of print) – open access publication |
| Vascular events may predict the prognosis of patients with chronic myeloid leukemia (Ureshino H & Kamachi K. Int J Hematol, August 2020) – open access publication |
Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia (Greiner L et al. Int J Cancer, August 2020) – open access publication |
| Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors (Lucijanic M & Krecak I. Int J Hematol, August 2020) – open access publication |
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia treated with TKIs or at diagnosis |
| Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study) (Genelli M et al. Blood Res, August 2020) (epub ahead of print) – open access publication |
Mutations in the BCR-ABL1 kinase domain in patients with chronic myeloid leukemia treated with TKIs or at diagnosis (Liu J et al. Oncol Lett, August 2020) – open access publication |
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo (Jyotsana N et al. Ann Hematol, August 2020) – open access publication |
|
| July 2020 | |
| A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukemia (Smith G et al. Br J Haematol, July 2020) (epub ahead of print) – open access publication |
PVR and ICAM-1 on blast crisis CML stem and progenitor cells with TKI resistance confer susceptibility to NK cells (Kim N et al. Cancers (Basel), July 2020) |
|
Is cancer latency an outdated concept? Lessons from chronic myeloid leukemia |
Tyrosine kinase inhibitors induce alternative spliced BCR-ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR-ABL (Yuda J et al. Cancer Sci, July 2020) – open access publication |
| Current treatment options for chronic myeloid leukemia patients failing second-generation tyrosine kinase inhibitors (García-Gutiérrez V & Hernández-Boluda JCC. J Clin Med, July 2020) – open access publication |
Integrin-linked kinase mediates therapeutic resistance of quiescent CML stem cells to tyrosine kinase inhibitors (Rothe K et al. Cell Stem Cells, July 2020) (epub ahead of print) |
| Surrogate markers for treatment-free remission in patients with chronic myeloid leukemia (Ureshino H et al. Clin Lymphoma Myeloma Leuk, July 2020) (epub ahead of print) - open access publication |
Therapeutic inhibition of FcγRIIb signaling targets leukemia stem cells in chronic myeloid leukemia (Parting O et al. Leukemia, July 2020) (epub ahead of print) - open access publication |
| Comparison of BCR-ABL1 quantification in pheripheral blood and bone marrow using an International scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia (Greiner G et al. Clin Chem Lab Med, July 2020) – open access publication |
Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells (Hallal R et al. J Cell Mol Med, July 2020) (epub ahead of print) – open access publication |
| Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia (Abaza Y et al. Am J Hematol, July 2020) (epub ahead of print) |
Targeting SKP2/BCR-ABL pathway with Diosmetin suppresses chronic myeloid leukemia proliferation (Liu Y et al. Eur J Pharmacol, July 2020) (epub ahead of print) |
| Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity (Janssen L et al. Haematologica, July 2020) |
|
| Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission (Rousselot P et al. Blood Adv, July 2020) – open access publication |
|
| Another set of guidelines for chronic myeloid leukaemia (Clark RE. Br J Haematol, July 2020) (epub ahead of print) |
|
| Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML) (Turhan AG et al. Leuk Lymphoma, July 2020) |
|
| Platelet function in patients with chronic myeloid leukemia treated with asciminib (Nesr G et al. Leuk Lymphoma, July 2020) (epub ahead of print) |
|
| Timing for allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients (Hu B et al. Leuk Lymphoma, July 2020) (epub ahead of print) |
|
| June 2020 | |
| The EUTOS long-term survival (ELTS) score is superior to the Sokol score for predicting survival in chronic myeloid leukemia (Pfirrmann M et al. Leukemia, June 2020) (epub ahead of print) - open access publication |
An integrative model of pathway convergence in genetically heterogenous blast crisis chronic myeloid leukemia (Ko TK et al. Blood, June 2020) (epub ahead of print) |
| First-line imatinib vs second- and third-generation TKI’s for chronic phase CML: a systematic review and data analysis (Vener C et al. Blood Adv, June 2020) – open access publication |
Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression (Sloma I et al. Haematologica, June 2020) (epub ahead of print) - open access publication |
| Influence of major BCR-ABL1 transcript subtype on outcomes in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib (Gentham A et al. Oncotarget, June 2020) – open access publication |
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitation and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia (Losson H et al. Pharmacol Res, June 2020) (epub ahead of print) |
| Current strategies and future directions to achieve deep molecular response and treatment-free remission in chronic myeloid leukemia (Annunziata M et al. Front Oncol, June 2020) – open access publication |
Micro RNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2 mediated autophagy (Li YL et al. Hum Cell, July 2020) |
| Chronic myeloid leukemia prognosis and therapy: Criticisms and perspectives (Russo D et al. J Clin Med, June 2020) – open access publication |
Inhibition of USP1, a new partner of BCR-ABL, results in decrease of BCR-ABL level in K562 cells (Antonenko SV et al. Exp Oncol June 2020) |
| Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study (Hochhaus A et al. Leukemia, June 2020) (epub ahead of print) - open access publication |
Blastic transformation of BCR-ABL1 positive chronic myeloid leukemia through acquisition of CBFB-MYH11 and mutant KIT (Shoumariyeh K et al. B J Haematol, June 2020) (epub ahead of print) -open access publication |
| How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the Italian Medicines Agency (AIFA) (Breccia M et al. Cancer Med, June 2020) – open access publication |
|
| Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 BCR-ABL1 transcripts in chronic myeloid leukemia (Pagani IS et al. Leuk Lymphoma, June 2020) (epub ahead of print) |
|
| The clinical impact of time to response in de Novo accelerated-phase chronic myeloid leukemia (Ohanian M et al. Am J Hematol, June 2020) (epub ahead of print) |
|
| May 2020 | |
| Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors (Hochhaus A et al. Leukemia, May 2020) (epub ahead of print) - open access publication |
Chronic myeloid leukemia with insertion-derived BCR-ABL1 fusion: redefining complex chromosomal abnormalities by correlation of FISH and karyotype predicts prognosis (Tang Z et al. Mod Pathol, May 2020) (epub ahead of print) |
|
High-risk additional chromosomal abnormalities at low blast counts herald death by CML |
Monitoring of minimal residual disease (MRD) in chronic myeloid leukemia: Recent advances (Cumbo C et al. Cancer Manag Res, May 2020) – open access publication |
| Analysis of chronic myeloid leukemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission (Machova Polakova K et al. Leukemia, May 2020) (epub ahead of print) |
Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts (Petiti J et al. J Clin Med, May 2020) – open access publication |
| Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukemia (Kaur U et al. Br J Haematol, May 2020) (epub ahead of print) - open access publication |
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells (Lernoux M et al. Clin Epigenetics, May 2020) – open access publication |
| Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations (Claudiadini S et al. Haematologica, May 2020) (epub ahead of print) - open access publication |
ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia (Joshi SK. Leukemia, May 2020) (epub ahead of print) - open access publication |
| Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years (Dulucq S et al. Br J Haematol, May 2020) – open access publication |
Coexistance of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in CML: A case report (Shi XB et al. World J Clin Cases, May 2020) – open access publication |
| Treatment-free remission in patients with chronic myeloid leukemia (Ross DM and Hughes TP. Nat Rev Clin Oncol, May 2020) (epub ahead of print) |
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia (Yu C et al. Haematologica, May 2020) – open access publication |
| Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results (SEER) analysis (Wang Q et al. Leuk Lymphoma, May 2020) |
Recruiting TP53 to target chronic myeloid leukemia stem cells Grant S. Haematologica, May 2020 – open access publication http://www.haematologica.org/content/105/5/1172 |
| ABL genomic editing sufficiently abolished oncogenesis of human chronic myeloid leukemia cells in vitro and in vivo (Chen SH et al. Cancers (Basel), May 2020) – open access publication |
|
| Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia (Ma CC et al. J Int Med Res, May 2020) – open access publication |
|
| High-risk additional chromosomal abnormalities at low blast counts herald death by CML (Hehlmann R et al. Leukemia, May 2020) (epub ahead of print) - open access publication |
|
| Novel multiplex droplet digital PCR assays to monitor minimal residual disease in chronic myeloid leukemia patients showing atypical BCR-ABL1 transcripts (Petiti J et al. J Clin Med, May 2020) – open access publication |
|
| Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia (Kumar R et al. Leukemia, May 2020) (epub ahead of print) - open access publication |
|
| Down-regulating NQO1 promotes cellular proliferation in K562 cells via elevating DNA synthesis (Xiao FY et al. Life Sci, May 2020) – open access publication |
|
| Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia (MA CC et al. J Int Med Res, May 2020) – open access publication |
|
| April 2020 | |
| Response and resistance to BCR-ABL1-targeted therapies (Braun TP et al. Cancer Cell, April 2020) |
Nobiletin promotes megakaryocytic differentiation through the MAPK/ERK-dependent EGR1 expression and exerts anti-leukemic effects in human chronic myeloid leukemia (CML) K562 cells (Yen JH et al. Cells, April 2020) – open access publication |
| Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased killer cells (Irani YD et al. Br J Haemaol, April 2020) (epub ahead of print) – open access publication |
Overexpression of IFIT2 inhibits the proliferation of chronic myeloid leukemia cells by regulating the BCR-ABL/AKT/mTOR pathway (Zhang Z et al. Int J Mol Med, April 2020) |
| Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia (Brümmendorf TH et al. Ann Hematol, April 2020) (epub ahead of print) - open access publication |
Genotype-phenotype correlation of unusual BCR-ABL1 transcripts in Philadelphia chromosome-positive leukemia (Gong Z et al. Br J Haematol, April 2020) (epub ahead of print) - open access publication |
| Venetoclax and BCR-ABL tyrosine kinase inhibitor combinations: outcome in patients with Philadelphia chromosome-positive advanced myeloid leukemias (Maiti A et al. Acta Haematol, April 2020) (epub ahead of print) |
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemia stem cells in CML (Lin H et al. Blood, April 2020) (epub ahead of print) |
| Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study (Cortes JE et al. Leukemia, April 2020) (epub ahead of print) – open access publication |
Response and resistance to BCR-ABL-1 targeted therapies (Braun TP et al. Cancer Cell, April 2020) |
| Metabolic analysis of patients with chronic myeloid leukemia and cardiovascular adverse events after treatment with tyrosine kinase inhibitors (Caocci et al. J Clin Med, April 2020) – open access publication |
GZD824 as a FLT3, FGFR1 and PDGFR-alpha inhibitor against leukemia in vitro and in vivo (Wang Y et al. Transl Oncol, April 2020) (epub ahead of print) - open access publication |
| Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring (Jabbour E and Kantarjian H. Am J Hematol, April 2020) (epub ahead of print) |
Basic knowledge on BCR-ABL1-positive extracellular vesicles (Jurj A et al. Biomark Med, April 2020) (epub ahead of print) |
| Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N-Road study (Nishiwaki K et al. Cancer Med, April 2020) (epub ahead of print) - open access publication |
Separase activity distribution can be a marker of major molecular response and proliferation of CD34+ cells in TKI-treated chronic myeloid leukemia patients (Spiess D et al. Ann Hematol, April 2020) (epub ahead of print) – open access publication |
| The differentiated diagnosis of basophilia in patients undergoing BCR-ABL testing (Smith CJ et al. Am J Hematol, April 2020) (epub ahead of print) - open access publication |
A novel chimeric antigen receptor redirecting T-cell specificity towards CCD26+ cancer cells (Zhou S et al. Leukemia, April 2020) (epub ahead of print) |
| Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia (Hino M et al. Int J Hematol, April 2020) (epub ahead of print) |
TKIs induce alternative spliced BCR-ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR-ABL (Yuda J et al. Cancer Sci, April 2020) (epub ahead of print) - open access publication |
| How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis frontline monitoring registries of the Italian Medicines Agency (AIFA) (Breccia M et al. Cancer Med, April 2020) (epub ahead of print) - open access publication |
Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides (Yang H et al. Cancer Lett, April 2020) (epub ahead of print) |
| Synthesis and characterization of Telmisartan-derived cell death modulators to circumvent imatinib resistance in chronic myeloid leukemia (Gust R et al. ChemMedChem, April 2020) (epub ahead of print) - open access publication |
|
| Role of DNA damage response in suppressing malignant progression of chronic myeloid leukemia and Polycythemia Vera: Impact of different oncogenes (Stetka J et al. Cancers (Basel), April 2020) – open access publication |
|
| March 2020 | |
| TARGET: a survey of real-world management of chronic myeloid leukemia across 33 countries (Turkina A et al. Br J Haematol, March 2020) (epub ahead of publication) |
Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse model (Zhang J et al. Br J Haematol, March 2020) (epub ahead of print) |
|
Risk stratification of chronic myeloid leukemia according to different prognostic scores |
An integrative model of pathway convergence in genetically heterogenous blast crisis chronic myeloid leukemia (Ko TH et al. Blood, March 2020) (epub ahead of print) |
| Patient-initiated discontinuation of tyrosine kinase inhibitor for chronic myeloid leukemia (Langabeer SE et al. Case Rep Hematol, March 2020) – open access publication |
Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and –resistant chronic myeloid leukemia cells (Jiang L et al. Eur J Pharmacol, March 2020) (epub ahead of print) – open access publication |
| European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (Hochhaus A et al. Leukemia, March 2020) (epub ahead of print) – open access publication |
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells (Shibata N et al. Oncogene, March 2020) (epub ahead of print) |
| Pharmacokinetics of dasatinib in hemodialysis patient with chronic myeloid leukemia and chronic kidney disease (Mori J et al. Int J Hematol, March 2019) (epub ahead of print) |
SIRT7: an influence factor in healthy aging and the development of age-dependet myeloid stem cell disorders |
| Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the new TARGET study 2nd line (Sakurai M et al. Int J Hematol, March 2020) (epub ahead of print) |
Ponatinib induces vascular toxicity through the Notch-1 signaling pathway (Madonna R et al. J Clin Med, March 2020) – open access publication |
| The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data (Luciano L et al. Eur J Haematol, March 2020) (epub ahead of print)- open access publication |
Involvement of MCL-1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315l(+) Ph+leukemia cells (Inoue C et al. Biochem Biophys Res Commun, March 2020) (epub ahead of print) |
|
Novel therapeutic approaches in chronic myeloid leukemia |
|
|
Experience of living with chronic myeloid leukemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies |
|
|
BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia |
|
| Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia (Eskazan AE. Leukemia, March 2020) (epub ahead of print) |
|
| Does patient sex play a role in treatment-free remission in chronic myeoid leukemia? (Ureshino H et al. Int J Hematol, March 2020) (epub ahead of print) |
|
| Significance of lymphocyte count, monocyte count, and lymphocyte-to-monocyte ratio in predicting molecular response in patients with chronic myeloid leukemia: A single center experience (Pepedil-Tanrikulu F et al. Clin Lab, March 2020) |
|
| Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients (Koutake Y et al. Int J Hematol, March 2020) (epub ahead of print) |
|
| February 2020 | |
| Side-effect profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia (Chan O et al. Blood Adv, February 2020) – open access publication |
Phosphorylation-dependent differences in CXCR4-LASP-AKT1 interaction between breast cancer and chronic myeloid leukemia (Butt E et al. Cells, February 2020) – open access publication |
| Prospects of achieving treatment-free remission in chronic myeloid leukemia) (Saglio G et al. Br J Haematol, February 2020) (epub ahead of print) - open access publication |
Aberrant RAG-mediated recombination contributes in lymphoid blast crisis of chronic myeloid leukemia (Thomson DW et al. Leukemia, February 2020) (epub ahead of print) |
| Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the past ten years (Dulucq S et al. Br J Hematol, February 2020) (epub ahead of print) |
Model-based inference and classification of immunological control mechanism from TKI cessation and dose reduction in CML patients (Hähnel T et al. Cancer Res, February 2020) (epub ahead of print) |
| Cardiovascular mortality among chronic myeloid leukemia patients in the pre-tyrosine kinase inhibitor (TKI) and TKI eras: a surveillance, epidemiology and end results analysis (Wang Q et al. Leuk Lymphoma, January 2020) (epub ahead of print) |
Comparison of BCR-ABL 1 quantification in peripheral blood and bone marrow using an international scale-standardized assay for assessment of deep molecular response in chronic myeloid leukemia (Greiner G et al. Clin Chem Lab Med, February 2020) (epub ahead of print) |
| Mechanisms of cardiovascular toxicity of BCR-ABL 1 tyrosine kinase inhibitors in chronic myelogenous leukemia (Gustafson D et al. Curr Hematol Rep, February 2020) (epub ahead of print) |
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia (Huang W et al. Leukemia, February 2020) (epub ahead of print) - open access publication |
| A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study (Etienne G et al. Br J Haematol, February 2020) (epub ahead of print) |
SRSF1 mediates cytokine induced impaired imatinib sensitivity in chronic myeloid leukemia (Sinnakannu JK et al. Leukemia, February 2020) (epub ahead of print) |
| Novel illumine-based next generation sequencing approach with one-round amplification provides early and reliable detection of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia (Romzova M et al. Br J Hematol, February 2020) (epub ahead of print) |
Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia (Adnan Awad S et al. Blood Adv, February 2020) – open access publication |
| What’s NEXT for CML-NGS mutation screening? (Shanmunagathan N et al. Blood, February 2020) |
The landscape of BCR-ABL mutations in patients with Philadelphia chromosome-positive leukaemias in the era of second-generation tyrosine kinase inhibitors |
| DNA damage and DNA damage response in chronic myeloid leukemia (Popp HD et al. Int J Mol Sci, February 2020) – open access publication |
|
|
Nanomaterials as magic bullets in the treatment of leukemia |
|
| January 2020 | |
| Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia (Masarova L et al. Cancer, January 2020) (epub ahead of print) |
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin SCT/TAL-1 – CD44 axis (Godavarthy PS et al. Haematologica, January 2020) – open access publication |
| Long-term results of frontline dasatinib in chronic myeloid leukemia (Maiti A et al. Cancer, January 2020) (epub ahead of print) |
How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study (Zhang H et al. J Biomol Strat Dyn January 2020) |
| Molecular dynamics during reduction of TKI dose reliably identify molecular recurrence after treatment cessation of CML (Gottschalk A et al. Blood, January 2020) (epub ahead of print) |
Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukemia patients stopping tyrosine kinase inhibitor therapy |
A randomized phase II trial of hydroxychloroquine and imatinib alone for patients with chronic myeloid leukemia in major cytogenetic response with residual disease |
The leukemia stem cell: similarities, differences and clinical prospects in CML and AML (Vetrie D et al. Nat Rev Cancer, January 2020) (epub ahead of print) |
| Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, January 2020) |
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy (Kinstrie R et al. Leukemia, January 2020) (epub ahead of print) |
| What are the considerations for tyrosine kinase inhibitor discontinuation in chronic phase chronic myeloid leukemia? (Harrington P et al. Expert Rev Hematol, January 2020) (epub ahead of print) |
Knock-out of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance (Herrmann AD et al. J Cell Mol Med, January 2020) (epub ahead of print) – open access publication |
|
Successful planned pregnancy through vitrified-warmed embryo transfer in a women with chronic myeloid leukemia: Case report and literature review |
Defining the niche interactions to target chronic myeloid leukemia stem cells (Mitchell R et al. Haematologica, January 2020) – open access publication |
| Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS study of the Kanto CL Study Group (Yamaguchi H et al. Int J Hematol, January 2020) (epub ahead of print) |
The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin – SCL/TAL1 – CD44 axis (Godavarthy PS et al. Haematologica, January 2020) – open access publication |
| Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells (Grandjenette C et al. Cancer Lett, January 2020) |
|
iCMLf Run.Ride.Cure 2020 - Wall of Fame
iCMLf Run.Ride.Cure 2020 Wall of Fame
This year the annual John Goldman charity run was virtual. With the help of 16 dedicated participants, including; previous preceptors, CML patients, colleagues and supporters - among them a six year old and an eight year old - we have raised more than $9,200 through the iCMLf Run.Ride.Cure 2020.
Thanks to everyone for their contributions!
iCMLf Run.Ride.Cure 2020 - Wall of Fame
This year the annual John Goldman charity run was virtual. With the help of 16 dedicated participants, including; previous preceptors, CML patients, colleagues and supporters - among them a six year old and an eight year old - we have raised more than $9,200 through the iCMLf Run.Ride.Cure 2020.
Thanks to everyone for their contributions!
iCMLf Conversations on CML and COVID-19 - Recordings of non-English conversations
You can view recordings of the 'iCMLf conversations on CML and COVID-19' in non-English languages here.
Additional conversations in Mandarin, Russian, Spanish and French will be made available over the next couple of weeks. The content of the presentations express the individual opinions of the respective experts.
CML Publications 2019
| Clinical Publications | Scientific Publications |
| December 2019 | |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEA CML WP (Baccarani M et al. Blood Adv. December, 2019) – open access publication |
Comprehensive analyses of safety and efficacy towards individualizing imatinib dosage in patients with chronic myeloid leukemia (Shin H et al. Int J Hematol, December 2019) (epub ahead of print) |
| Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in CML study (Soverini S et al. Blood, December 2019) (epub ahead of print) |
A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells (Brachet-Botineau M et al. Cancers (Basel), December 2019) |
| Tyrosine kinase inhibitors in leukemia and cardiovascular events: From mechanisms to patient care (Manouchehri A et al. Arterioscler Thromb Vasc Bio, December 2019) (epub ahead of print) – open access publication |
Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia (Ni J et al. Leuk Lymphoma, December 2019) (epub ahead of print) |
|
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia |
Reconstituion of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation |
| Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia (Chen Y et al. Clin Lymphoma Myeloma Leuk, December 2019) |
Macrophage protects mycoplasma-infected chronic myeloid leukemia cells from NK cell killing (Choo QWW et al. Immunol Cell Biol, December 2019) (epub ahead of print) |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure (Hughes TP et al. N Eng J Med, December 2019) |
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper (Soverini S et al. J Hematol Oncol, December 2019) - OPEN ACCESS |
| Do persons with chronic myeloid leukemia have normal or near normal survival? (Radivoyevitch T et al. Leukemia, December 2019) (epub ahead of print) - OPEN ACCESS |
Chronic myeloid leukemia: The danger of not knowing your BCR-ABL1 transcript (Sharplin K et al. Leuk Res, December 2019) |
| Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: An update (Bavaro L et al. Int J Mol Sci, December 2019) - OPEN ACCESS |
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia (Gupta P et al. Cancer Lett, December 2019) (epub ahead of print) |
| Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: A systematic review and meta-analysis (García-Ferrer M et al. Clin Ther, December 2019) |
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia (Hillis S et al. Leuk Res, December 2019) (epub ahead of print) |
| Treatment-free remission in chronic myeloid leukemia (Molica M et al. Clin Adv Hematol Oncol, December 2019) |
Blast crisis of chronic myeloid leukemia with plasmacytoid dentritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1 (Xu D et al. Leuk Lymphoma, December 2019) |
| Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors (Santoro M et al. Chemotherapy, December 2019) (epub ahead of print) |
|
| November 2019 | |
| Sudden blastic transformation in treatment-free remission chronic myeloid leukemia (Alfayez M et al. Br J Haematol, November 2019) |
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission |
| New approaches to molecular monitoring in CML (and other diseases) (Radich J et al. Blood, November 2019) |
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Lauseker M et al. Am J Hematol, November 2019) |
|
Compexity of chronic-phase CML management after failing a second-generation TKI |
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells (Tanaka A et al. J Exp Med, November 2019) (epub ahead of print) |
| Towards a personalized treatment of patients with chronic myeloid leukemia (Rabian F et al. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
Role of cancer immunology in chronic myelogenous leukemia (Ureshino H et al. Leuk Res, November 2019) (epub ahead of print) |
| The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt (Legros L et al. Blood, November 2019) |
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315l clones in TKI-resistant CML (Schneeweiss-Gleixner M et al. EBioMedicine, November 2019) (epub ahead of print) |
| Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): A FI-LMC STOP 2G-TKI study update (Rea D et al. Blood, November 2019) |
Repurposing drugs in silico methods to target BCR kinase domain in chronic myeloid leukemia (Natarjan A et al. Asian Pac J Cancer Prev, November 2019) http://journal.waocp.org/article_88830.html |
| Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also bEarly management of CML (Shanmunagathan N et al. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
Druggable biochemical pathways and potential therapeutic alternatives to target leukemia stem cells and eliminate the residual disease in chronic myeloid leukemia |
| Introducing a predictive score for successful treatment-free remission in chronic myeloid leukemia (CML) (Claudiani S et al. Blood, November 2019) |
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia (Lernoux M et al. Biochem Pharmacol, November 2019) (epub ahead of print) |
|
Early management of CML |
The hidden pathogenesis of CML: Is BCR-ABL1 the first event? (Shanmunagathan N, Branford S. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
| October 2019 | |
| Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia (Franke GN et al. J Mol Diagn, October 2019) (epub ahead of print) |
Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants (Eide CA et al. Cancer Cell, October 2019) |
| Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study (Shah NP et al. Leuk Lymph, October 2019) (epub ahead of print) |
|
| Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type (Baccarani et al. Leukemia, October 2019) |
|
| September 2019 | |
| Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations (Claudiani S et al. Haematologica, September 2019) (epub ahead of print) |
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Magistroni V et al. Haematologica, September 2019 |
| Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia (Naqvi K et al. Cancer, September 2019) (epub ahead of print) |
Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells (Okabe S et al. Leuk Lymphoma, September 2019) (epub ahead of print) |
| New approaches of molecular monitoring in CML (and other diseases) (Radich J et al. Blood, September 2019) (epub ahead of print) |
KLF4 represses DYRK2 inhibition of self-renewal and survival through c-Myc and p53 in leukemia stem/progenitor cells (Park CS et al. Blood, September 2019) (epub ahead of print) |
| Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy (Efficace F et al. Leukemia, September 2019) (epub ahead of print) |
MiR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation (Huang T et al. Biomed Pharmacother, September 2019) (epub ahead of print) |
| Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt) (Nagafuji K et al. J Hematol, September 2019) (epub ahead of print) |
The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib (Bestach Y et al. Leuk Res, September 2019) (epub ahead of print) |
| Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy (Tiribelli M et al. Ann Hematol, September 2019) |
The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia (Xu H et al. Leuk Lymphoma, September 2019) (epub ahead of print) |
| Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States (Abou Dalle I et al. Cancer Med, September 2019) (epub ahead of print) |
|
| Tyrosine kinase inhibitors in the clinical setting: A conundrum of choices (Bankar A et al. Acta Haematol, September 2019) |
|
|
Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial |
|
| August 2019 | |
| Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Lauseker M et al. Am J Hematol, August 2019) (epub ahead of print) |
BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis (Kidoguchi K et al. Ann Hematol, August 2019) (epub ahead of print) |
| Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type (Baccarani M et al. Leukemia, August 2019) (epub ahead of print) |
Continuous cytostatic effects of BCR-ABL tyrosine kinase inhibitors (TKI’s) after washout in human leukemic K562 cells (Aoyama T et al. Biol Pharm Bull, August 2019) (epub ahead of print) |
| Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, August 2019) (epub ahead of print) |
Identification of key candidate targets and pathways for the treatment of leukemia using bioinformatics analysis (Li H et al. Mol Genet Genomic Med, August 2019) (epub ahead of print) |
| Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukemia (Ross DM et al. Br J Haematol, August 2019) |
Bone marrow microenvironment: The guardian of leukemia stem cells (Houshmand M et al. World J Stem Cells, August 2019) |
| Treatment patterns and deep molecular response in chronic phase chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, August 2019) (epub ahead of print) |
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of surviving and cyclin D1 in chronic myeloid leukemia cells (Moriyama K et al. Int J Hematol, August 2019) (epub ahead of print) |
| Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogenous leukemia – You can do this if you read the instructions (Schiffer CA. Haematologica, August 2019) |
Combined inhibition of MDM2 and BCR-ABL tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model (Carter BZ et al. Haematologica, August 2019) (epub ahead of print) |
| The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia (Aoyama R et al. J Cardiol, August 2019) (epub ahead of print) |
Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia (Yu C et al. Haematologica, August 2019) (epub ahead of print) |
| Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukemia in chronic phase: a prospective observational study in daily clinical practice (Huguet F et al. Br J Haematol, August 2019) (epub ahead of print) |
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of surviving and Cyclin D1 in chronic myeloid leukemia cells (Moriyamo K et al. Int J Hematol, August 2019) (epub ahead of print) |
| Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in real-life practice (Caocci G et al. Ann Hematol, August 2019) |
Targeting small molecule tyrosine kinases by Polyphenols: New move towards anti-tumor drug discovery (Sakle NS et al. Curr Drug Discov Technol, August 2019 (epub ahead of print) |
| New approaches and treatment combinations for the management of chronic myeloid leukemia (Westerweel PE et al. Front Oncol, August 2019) |
|
| FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukemia patients with tyrosine kinase inhibitor therapy (Haidary AM et al. Malays J Pathol, August 2019) |
|
| Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase exposure: A Blood or Marrow transplant Survivor Study (BMTSS) Report (Wu J et al. Cancer, August 2019) (epub ahead of print) |
|
| Outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline (Crugnola M et al. Ann Hematol, August 2019) (epub ahead of print) |
|
| Recommendations from a Portuguese expert group for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients in clinical practice (Almeida A et al. Acta Med Port, August 2019) (epub ahed of print) |
|
| July 2019 | |
| Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome (Berger MG et al. Br J Haematol, July 2019) (epub ahead of print) |
Oncurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments (Sheng G et al. Leuk Lymphoma, July 2019) (epub ahead of print) |
| Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors (Etienne G et al. Cancer Med, July 2019) (epub ahead of print) |
Targeting BCR-ABL 1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation (Burslem GM et al. Cancer Res, July 2019) (epub ahead of print) |
| Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients (Nicolini FE et al. Clin Cancer Res, July 2019) (epub ahead of print) |
Killer immunoglobulin-line receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission (Dumas PY et al. Cancer Med, July 2019) (epub ahead of print) |
| Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test (Kondo T et al. Int J Hematol, June 2019) (epub ahead of print) |
Infliximab together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia (Herrmann O et al. BMC Cancer, July 2019) |
| Digital droplet PCR at the time of TKI discontinuation in chronic phase chronic myeloid patients is predictive of treatment-free remission outcome (Colafigli G et al. Hematol Oncol, July 2019) (epub ahead of print) |
Human BCR-ABL1 induces chronic myeloid leukemia-like disease in zebrafish (Xu M et al. Haematologica, July 2019) (epub ahead of print) |
| True value of second-generation TKI’s as first-line therapy in chronic myeloid leukemia (Andrews CN et al. Lancet Haematol, June 2019) (epub ahead of print) |
Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts (Xue M et al. Leuk Lymphoma, July 2019) (epub ahead of print) |
| Front-line use of tryrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations (Reff MJ et al. J Oncol Pharm Pract, July 2019) (epub ahead of print) |
Determination of serum imatinib and it’s metabolite in patients with chronic myeloid leukemia (Onmaz DE et al. Clin Chim Acta, July 2019) (epub ahead of print) |
| Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety (García-Gutiérrez V et al. Front Oncol, July 2019) |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in PH+ leukemia and sensitizes for ABL kinase inhibitors (Bahjat M et al. Cell Cycle, July 2019) (epub ahead of print) |
| Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: results from a population-based study (Lauseker M et al. Eur J Haematol, July 2019) (epub ahead of print) |
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/line cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment (Trojani A et al. PLoS One, July 2019) (epub ahead of print) |
| Comparison of BCR-ABL transcript variants between patients with chronic myeloid leukemia and leukemia cell lines (DE Oliveira Sales L et al. In Vivo, July-Aug 2019) |
|
| June 2019 | |
|
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series |
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells (Abraham A et al. J Clin Invest, June 2019) |
| De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukemia (DESTINY): a non-randomized, phase 2 trial (Clark RE et al. Lancet Haematol, June 2019) (epub ahead of print) |
Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key? (Bernardi S et al. Eur J Haematol, June 2019) (epub ahead of print) |
| Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukemia: a modeling study (Shih YT et al. Lancet Haematol, June 2019) (epub ahead of print) |
Knockdown of ribonucelotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy (Liu C et al. Oncol Rep, June 2019) (epub ahead of print) |
| Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia (Dragani M et al. Leuk Lymphoma, June 2019) (epub ahead of print) |
Clinical implications of simultaneous occurrence of variant Philadelphia translocations in chronic myeloid leukemia (Trivedi P et al. J Assoc Genet Technol, 2019) |
| Therapy de-escalation before stopping in chronic myeloid leukemia (Mustjoki S et al. Lancet Haematol, June 2019) (epub ahead of print) |
|
| Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy (Dou X et al. Oncologist, June 2019) (epub ahead of print) |
|
| Is there a role for dose modification of TKI therapy in CML? (Copland M. Curr Hematol Malig Rep, June 2019) (epub ahead of print) |
|
| May 2019 | |
| NCCN Guidelines updates: Discontinuing TKI therapy in the treatment of chronic myeloid leukemia (Shah NP et al. J Natl. Compr Canc Netw, May 2019) |
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib (Kok CH et al. Blood Adv, May 2019) |
| Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data (Breccia M et al. Acta Haematol, May 2019) (epub ahead of print) |
Outcomes of patients with chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy (Boddu P et al. Leuk Lymphoma, May 2019) (epub ahead of print) |
| Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life (Molica M et al. Ann Hematol, May 2019) (epub ahead of print |
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors (Nteliopoulos G et al. Haematologica, May 2019) (epub ahead of print) |
| Patients’ perspective on the definition of cure in chronic myeloid leukemia (Flynn KE et al. Leuk Res, May 2019) |
The proportion of different transcript types in chronic myeloid leukemia: An international review (Baccarani M et al. Leukemia, May 2019) |
| Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors (Jamy O et al. Leuk Res, May 2019) (epub ahead of print) |
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia |
| Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options (Sundaram DNM et al. Drug Discov Today, May 2019) (epub ahead of print) |
Digital PCR in myeloid malignancies: Ready to replace quantitative PCR? |
| Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response (Rostami G et al. Mol Genet Genomic Med, May 2019) (epub ahead of print) |
|
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo (Jyotsana N et al. Ann Hematol, May 2019) (epub ahead of print) |
|
| Validation of a Drosophila model of wild type and T315l mutated BCR-ABL1 in chronic myeloid leukemia: An effective platform for treatment screening (Al Outa A et al. Haemotologica, May 2019) (epub ahead of print) |
|
| PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells (Ivanova ES et al. Int J Oncol, May 2019) (epub ahead of print) |
|
|
|
Chronic myeloid leukemia stem cells |
| April 2019 | |
| A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hemotopoietic cell transplantation (Bezerra ED et al. Leuk Lymphoma, April 2019) |
Antitumor efficacy of arsenal/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors |
| The outcomes of chronic myeloid leukemia patients with molecular warning responses during imatinib treatment according to the European LeukemiaNet 2013 recommendations (Soysal T et al. Clin Lymphoma Myeloma Leuk, April 2019) (epub ahead of print) |
The vascular bone marrow niche influences outcomes in chronic myeloid leukemia via the E-selectin-SCL/TAL1-CD44 axis |
| Patient-reported outcomes in the phase 2 BEFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia (Cortes JE et al. J Cancer Res Clin Oncol, April 2019) (epub ahead of print) |
Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission (Shanmuganathan N et al. Blood, April 2019) (epub ahead of print) |
| Matching-adjusted indirect comparison of bosutinib, dasatinib, and nilotinib on survival and major cytogenetic response for treatment of second-line chronic phase chronic myeloid leukemia (Cortes JE et al. Curr Med Res Opin, April 2019) (epub ahead of print) |
Compound mutations in CML – imaginary bogeyman or real arch-nemesis? (Yeung DT. Leuk Res, April 2019) |
|
Exploring patient decision making regarding discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia |
Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against cancer qPCR assay |
| Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor (Möbius S et al. J Cancer Res Clin Oncol, April 2019) (epub ahead of print) |
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia (Wang R et al. Medicine, April 2019) |
|
Anthropometric facts and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis |
|
| March 2019 | |
| MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia (Claudiani S et al. Haematologica, March 2019) (epub ahead of print) |
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitors (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) (Wu J et al. Cancer Biol Ther, March 2019) (epub ahead of print) |
|
Lenalidomine maintenance after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukemia |
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis |
| Nilotinib in the treatment of chronic myeloid leukemia (Sacha T et al. Future Oncol, March 2019) |
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation (Uchida E et al. Int J Oncol, March 2019) (epub ahead of print) |
| Analysis of cardiovascular and arteriothrombotic events in chronic-phase CML patients after frontline TKI’s (Jain P et al. Blood Adv, March 2019) |
A synergistic combination against chronic myeloid leukemia: An intra-molecular mechanism of communication in BCR-ABL1 resistance (El Rashedy AA et al. Protein J, March 2019) (epub ahead of print) |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (Score) chart (Caocci G et al. Hematol Oncol, March 2019) (epub ahead of print) |
Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling (Kuepper MK et al. Leukemia, March 2019) (epub ahead of print) |
| Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (Janssen L et al. Leukemia, March 2019) (epub ahead of print) |
Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia (Krishna Chandran R et al. Front Oncol, March 2019) (epub ahead of print) |
| Incidence of second malignancies in patients with chronic myloid leukemia in the era of tyrosine kinase inhibitors (Sasaki K et al. Int J Hematol, March 2019) (epub ahead of print) |
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact an inclusion of CML patients in stopping trials (Spiess B et al. PLos One, March 2019) |
| Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia (Mauro MJ. Curr Opin Hematol, March 2019) |
Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review) (Lee HR et al. Oncol Rep, March 2019) (epub ahead of print) |
|
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities |
|
|
Can increased immunogenicity in chronic myeloid leukemia improve outcomes? |
|
|
Can increased immunogenicity in chronic myeloid leukemia improve outcomes? |
|
| February 2019 | |
| Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice (Fava C et al. Haematologica, February 2019) (epub ahead of print) |
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Magistroni V et al. Haematologica, February 2019) (epub ahead of print) |
| Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI (Shanmunagathan N et al. Blood Adv, February 2019) |
Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia (Ferri C et al. Gene, February 2019) (epub ahead of print) |
| Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line (Dulucq S et al. Ann Hematol, February 2019) (epub ahead of print) |
PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL 1 dependent (Nandagopalan SR et al. Int J Biochem Cell Biol, February 2019) (epub ahead of print) |
| Chronic myeloid leukaemia in pregnancy: call for guidelines (Pallavee P et al. J Obste Gynaecol, February 2019) (epub ahead of print) |
Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale (Furuya D et al. Int J Clin Oncol, February 2019) (epub ahead of print) |
|
The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors |
Imatinib treatments have long-term impact on placentation and embryo survival (Salem W et al. Sci Rep, February 2019) |
| Everolimus in combination with imatinib overcomes resistance in chronic myeloid leukemia (Alves R et al. Med Oncol, February 2019) |
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients |
|
Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis |
High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance (Ping L et al. Oncol Res, February 2019) |
| Efficacy and safety of tyrosine kinase inhibitors for newly myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system (Kizaki M et al. Int J Hematol, February 2019) (epub ahead of print) |
MiR-378 promoted cell proliferation and inhibited apoptosis by enhance stem cell properties in chronic myeloid leukemia K562 cells |
| January 2019 | |
| Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib (Latifi Y et al. Blood, January 2019) (epub ahead of print) |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: An international overview (Baccarani M et al. Leukemia, January 2019) (epub ahead of print) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (Chamoun K et al. J Hematol Oncol, January 2019) |
Prediction of ALK mutations mediating ALK-TKI’s resistance and drug re-purposing to overcome the resistance (Okada K et al. E-Bio Medicine, January 2019) (epub ahead of print) |
| The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia (Lasica M et al. Leuk Lymphoma, January 2019) (epub ahead of print) |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: An international overview (Baccarani M et al. Leukemia, January 2019) (epub ahead of print) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (Chamoun K. J Hematol Oncol, January 2019) |
New tool for monitoring molecular response in patients with chronic myeloid leukemia (Badar T et al. Appl Immunohistochem Mol Morphol, January 2019) |
|
Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib |
NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia (Chang MC et al. Front immunol, January 2019) |
|
Long-term disease control in chronic myeloid leukemia |
A novel naphtoquine-coumarin hybrid that inhibits BCR-ABL1-STAT5 oncogenic pathway and reduces survival in imatinib-resistant chronic myelogenous leukemia cells (Martín-Rodríguez P et al. Front Pharmacol, January 2019) |
|
The case for real-world evidence in the future of clinical research on chronic myeloid leukemia |
Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia (Xie J et al. Oncol Lett, January 2019) |
| Risk and challenges of CML management during pregnancy: looking for a balanced decision (Chelysheva E et al. Eur J Haematol, January 2019) (epub ahead of print) |
Twins with two different personalities: STAT5B but nocht STAT5A has a key role in BCR/ABL-induced leukemia (Kollmann S et al. Leukemia, January 2019) (epub ahead of print) |
